Data as-of 2026-07-28 close.

No name in this 21-ticker cut sits below RSI 40 for the first time in several scans — ISRG, MRNA, and HROW, the sector's three oversold prints last time, all graduated upward. ABT had the biggest single move: RSI 68.3 → 73.3, +16.53% over 30 days, crossing into overbought alongside AMGN (64.1 → 72.8). TMO held near the top (71.0 → 70.3). ISRG's recovery is the notable middle case — RSI 31.4 → 42.4, 52-week-high gap -45.0% → -40.1% — but its regime classifier still reads "collapse."

Source: healthcare.json (the broader 21-name universe, not the narrower healthcare-scan.json cut). Latest bar 2026-07-28 for every name in this cut. Prior scan: 2026-07-25-healthcare-scan.

ABT posted the biggest single move in the cut. RSI climbed from 68.3 to 73.3 — crossing into overbought — on +16.53% over 30 days (change30d per healthcare.json), the largest 30-day gain anywhere in this scan. AMGN crossed the same threshold, RSI 64.1 → 72.8, +9.03% over 30 days. TMO — the sole overbought name last scan — held near the top rather than extending further, 71.0 → 70.3. All three are now extended enough that a fresh entry means chasing, not buying a pullback.

ISRG is the cut's most instructive middle case, and the same story shows up in this session's biotech cut for the identical ticker: RSI moved from 31.4 to 42.4, out of the oversold band entirely, and the gap to its 52-week high narrowed from -45.02% to -40.09%. Both are real improvements. But the regime classifier still reads "collapse," the trend is strong-down DC, and the thesis flag on file still reads "intact" — better tape, unconfirmed structure.

The sector's other two previously-oversold names both improved without fully resolving. MRNA moved 36.7 → 40.3, still down -19.93% over 30 days. HROW moved 39.9 → 43.5, still down -10.04% over the week even after last scan's sharp break. Neither has posted a clean reversal signal yet. ZTS climbed further out of its weak band, 45.5 → 52.7, though it remains -51.70% off its own 52-week high — improved momentum sitting on top of a still-deeply-damaged chart.

Away from those extremes, a broad middle held steady or improved modestly: SYK, VEEV, MRK, MDT, JNJ, and CVS all sit in the RSI 60s with no single name badly extended — the cleanest zone in the cut for a fresh look.

• The oversold band emptied out entirely. ISRG, MRNA, and HROW — the sector's three sub-40 prints last scan — all moved above RSI 40; no name remains below that line.
• ABT had the biggest single move. RSI 68.3 → 73.3, +16.53% over 30 days — now overbought.
• AMGN crossed into overbought. RSI 64.1 → 72.8, +9.03% over 30 days.
• TMO held near the top rather than extending. RSI 71.0 → 70.3.
• ISRG recovered meaningfully but stayed in a "collapse" regime. RSI 31.4 → 42.4; 52-week-high gap -45.0% → -40.1%.
• ZTS climbed further out of its weak band. RSI 45.5 → 52.7, though still -51.7% off its 52-week high.
• HROW improved from its sharp break last scan but hasn't reversed. RSI 39.9 → 43.5, still -10.04% over the week.
• SYK had a strong week. RSI 56.2 → 62.9, +10.18% over the week.
• GH cooled from its prior read. RSI 48.8 → 45.8.
• Universe unchanged. Same 21 tickers as the July 25 healthcare.json cut — no composition change.

RSI measures how stretched a stock is over the past 14 sessions — under 30 is oversold, over 70 is overbought/extended. vs SMA20 is the price gap to the 20-day average. vs VWAP is the premium over the average price paid by current holders — a useful gut check on how much of a move is unrealized gain that could get sold into weakness. Trend combines direction/strength with a cross signal: GC (golden cross) is structurally healthier than DC (death cross). A stock whose RSI recovers out of the oversold band while the regime classifier still reads "collapse" — like ISRG here — means the price move hasn't been confirmed by the underlying structure; treat it as "watch," not "buy."

None.

None. For the first time in several scans, every name in this cut sits above RSI 40 — the sector's three prior sub-40 prints (ISRG, MRNA, HROW) all moved up.

• Cooling (RSI 41-49): MRNA, ISRG, HROW, GH. ISRG is the standout for real tape improvement despite a still-"collapse" regime.
• Basing (RSI 50-59): ZTS, BIIB, DXCM, UNH, VRTX, GILD. None extended, none broken — the cleanest zone in the cut.
• Momentum / overbought (RSI 60+): PFE, LLY, SYK, VEEV, MRK, MDT, JNJ, CVS, TMO, AMGN, ABT. Three of these (TMO, AMGN, ABT) are now above the 70 overbought line — up from one last scan.

• The oversold band emptied out entirely this scan — does it stay clear, or does the next pullback refill it?
• ABT and AMGN both just crossed into overbought alongside TMO — does the cluster keep extending, or does it give back the way LEGN did in this session's biotech cut?
• ISRG's tape improved (RSI 31.4 → 42.4, 52wk-high gap narrower) while its regime still reads "collapse" — which read wins over the next scan?
• ZTS climbed to RSI 52.7 but remains -51.7% off its 52-week high — is that a genuine floor forming, or a bounce inside a still-broken chart?

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-28 close — healthcare.